FCF Life Sciences Venture Capital Monitor – Europe 04/2021 published

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences Venture Capital Monitor – Europe 04/2021”.

The Monitor is a monthly published overview of venture capital trends in the European Life Sciences sector.

As of the end of April 2021 we identify the following current VC trends in Europe:

  • In 2021, overall Life Sciences funding has reached EUR 4,288m so far
  • Top 5 Deals exceed EUR 140m each, largest transaction amounted to
    EUR 253m in Kry International AB (Sweden)
  • BlackRock (USA) still dominates the Top 5 Investors (by deal volume), followed by Fidelity Management & Research (USA) and Novo Holdings (Denmark)
  • The Biotechnology sector received 65% of the total investment volume (-11% points compared to the previous month)
  • Central Nervous System replaces Oncology as the top indication

To access the full report, please click here.

By Dr. Mathias Schott, Sebastian Sommer and Alexander Kuhn

Share
[a-zA-Z0-9_.-]
[a-zA-Z0-9_.-]
[a-zA-Z0-9]
[a-zA-Z0-9]